Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05396456 · ClinicalTrials.gov registry record · NA

Autologous Muscle Fiber Fragment Injections

A NA study of Fecal Incontinence, sponsored by Wake Forest University Health Sciences.

Recruiting
Registry status
NA
Development phase
10
Enrollment target
1
Study location

NCT05396456: Recruiting NA study of Fecal Incontinence, sponsored by Wake Forest University Health Sciences.

NCT05396456 is a NA study of Fecal Incontinence that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 10 participants, below the 335-participant average among 22 other Fecal Incontinence trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05396456, a NA study of Fecal Incontinence, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.

RECRUITING
Registry status
NA
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

To regenerate functional anal sphincter muscle using muscle fiber fragments that contain muscle precursor cells (MPCs)

Primary Outcome

fecal incontinence score from 0-20; where 0 is perfect continence and 20 is complete incontinence

Conditions Studied

Interventions

  • PROCEDURE Muscle Fiber Fragment (MFF) Injections

Study Locations (1)

North Carolina

  • Wake Forest University Health Sciences - Winston-Salem

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2023-01-12
Est. Completion 2029-12
Phase NA
Wake Forest University Health Sciences

1,140 total trials

What NCT05396456 shows while recruiting

NCT05396456 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 335-participant average among 22 other Fecal Incontinence trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Fecal Incontinence appearing as the primary indexed condition, and to 1 intervention - of which Muscle Fiber Fragment (MFF) Injections is the first listed.

NCT05396456 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT05396456 about?

NCT05396456 is a clinical study titled "Autologous Muscle Fiber Fragment Injections". To regenerate functional anal sphincter muscle using muscle fiber fragments that contain muscle precursor cells (MPCs)

What is the current status of trial NCT05396456?

This trial is currently recruiting. It is a NA study. The enrollment target is 10 participants. The study started on 2023-01-12. Estimated completion is 2029-12.

What conditions does trial NCT05396456 study?

This clinical trial studies the following conditions: Fecal Incontinence.

What interventions are being tested in trial NCT05396456?

The interventions under investigation include: Muscle Fiber Fragment (MFF) Injections (PROCEDURE).

Who is sponsoring clinical trial NCT05396456?

This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05396456 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Fecal Incontinence

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05396456's enrollment target sits among peer trials

10 19th of 22 higher than 2 of 22 other Fecal Incontinence trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Fecal Incontinence trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00623389 · 10 participants · NA

    Evaluation of an Advanced Lower Extremity Neuroprostheses

  • NCT01241864 · 10 participants · Phase 2

    Islet Transplantation in Type 1 Diabetic Kidney Allograft

  • NCT01293214 · 10 participants · NA

    Vascularized Composite Allotransplantation for Multiple Extremity Amputations

  • NCT01474148 · 10 participants · NA

    A Neuroprosthesis for Seated Posture and Balance

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05396456, the US trial registry maintained by the National Library of Medicine. NCT05396456 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.